David D. Allen, R.Ph, Ph.D, FASHP

Reportable Conflicts of Interests:  None

Disclosure of Financial Conflicts of Interest: None

Education:
Doctor of Philosophy in Pharmaceutical Sciences
Univerisity of Kentucky
College of Pharmacy, Pharmacology, and Experimental Therapeutics Division
Lexington, Kentucky

 

Bachelors of Science in Pharmacy
University of Kentucky
College of Pharmacy
Lexington, Kentucky

 

Post Graduate or Residency Training:

Post-Doctoral Fellowship
Intramural Research Training Award Fellow
Neurochemistry and Brain Transport Section
Laboratory of Neurosciences
National Institute on Aging
National Institutes of Health
Bethesda, Maryland

Current Position or Practice Site:
Graduate Faculty in Pharmacology
School of Biomedical Sciences
Kent State University

Professor of Pharmacology and Physiology
Department of Integrative Medical Sciences
Northeastern Ohio Universities College of Medicine

Dean of Pharmacy
Northeastern Ohio Universities College of Pharmacy

Professor of Pharmaceutical Sciences (Tenured)
Department of Pharmaceutical Sciences
Northeastern Ohio Universities College of Pharmacy

Past Positions and/or Appointments:
Professor of Pharmacology and Physiology
Department of Pharmacology and Physiology
Northeastern Ohio Universities College of Medicine

Graduate Faculty in Pharmaceutical Sciences (Associate Member)
Graduate School of Biomedical Sciences
Texas Tech University Health Sciences Center

Founding Dean
Northeastern Ohio Universities College of Pharmacy
Rootstown, Ohio

Consultant Dean of Pharmacy
Northeastern Ohio Universities College of Medicine
Rootstown, Ohio

Visiting Scholar with Dr. Victor A. Yanchick, Dean
Virginia Commonwealth University School of Pharmacy
Medical College of Virginia Campus

Associate Dean for Curricular Affairs
TTUHSC School of Pharmacy
Amarillo, Texas

Associate Professor, Department of Pharmaceutical Sciences (Tenured)
TTUHSC School of Pharmacy
Amarillo, Texas

Graduate Faculty in Pharmaceutical Sciences (Auxiliary Member)
The Graduate School
University of Kentucky

Graduate Faculty in Pharmaceutical Sciences
Graduate School of Biomedical Sciences
Texas Tech University Health Sciences Center

Vice-Chair
Department of Pharmaceutical Sciences
TTUHSC School of Pharmacy

Assistant Professor
Department of Pharmaceutical Sciences
TTUHSC School of Pharmacy

Graduate Research Assistant
Division of Pharmacology and Experimental Therapeutics
College of Pharmacy
University of Kentucky

Undergraduate Research Assistant
Division of Pharmacology and Toxicology
College of Pharmacy
University of Kentucky

Instructor
Pharmaceutical Technology
Phillips College

Staff Pharmacist, Part-time
Northwest Texas Healthcare Systems Hospital
Amarillo, Texas


Pharmacist, Part-time
CVS Pharmacy
Wheaton, Maryland

Pharmacist, Part-time
Home Convalescent Aids Pharmacy
Winchester, Kentucky

Pharmacist, Part-time
Northside Pharmacy
Lexington, Kentucky

Pharmacist, Part-time
Walgreen Co.
Louisville, Kentucky

Chief Pharmacist
Walgreen Co.
Louisville, Kentucky

Chief Pharmacist
Walgreen Co.
Palm City, Florida

Pharmacist
Walgreen Co.
Port St. Lucie, Florida

Professional Memberships:

American Association of Pharmaceutical Scientists

Society for Neuroscience

Sigma Xi, The Scientific Research Society

American Society of Health-System Pharmacists

American Pharmacists Association

American College of Clinical Pharmacy

American Association of Colleges of Pharmacy

Ohio Pharmacy Consortium

Council of Ohio Colleges of Pharmacy

Ohio Society of Health-System Pharmacists

Ohio College of Clinical Pharmacy

Ohio Pharmacists Association

Texas Society of Health-System Pharmacists

 

Grant Activity:
Development of Novel Treatments for Nicotine Addiction. RFA. National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland. U19 MH069059-01. Total direct and indirect costs $6,570,832. Linda P. Dwoskin, Ph.D., Principal Investigator. Subcontract $347,612 total direct and indirect costs. David D. Allen, R.Ph., Ph.D., Subcontract Principal Investigator for Project 1. July 1, 2003 – June 30, 2008. (Subcontract Principal Investigator role changed to Co-Investigator, January, 2006). Funded. One year no cost extension through June 30, 2009.

 

Tobacco Smoke Chemicals and Stroke Alter Brain K+ Efflux. NINDS, National Institutes of Health # 1 RO1 NS 046526-01, Bethesda, Maryland. Co-Investigator. April 1, 2004 – March 31, 2009. $1,685,058 total direct and indirect costs. Funded.

 

Application for a Blood-Gas/Blood-chemistry Analyzer. TTUHSC School of Pharmacy, Amarillo, Texas. $12,000 (match with $3,000 matching funds). Funded. Principal Investigator. March, 2003.

 

Unrestricted Grant for In Situ Rat Brain Perfusion Studies. Absorption Systems, Inc. Exton, Pennsylvania. $7,500 direct and indirect costs. Principal Investigator. March 15, 2002 – March 14, 2003. Funded.

 

Nanotemplate Engineering of Cell-Specific Nanoparticles. National Institutes of Health, NIBIB. Bethesda, Maryland. R21 Award. EB00531-01. $300,863. Funded. External Principal Investigator via subcontract to the University of Kentucky Research Foundation. Total Texas Tech University HSC School of Pharmacy Award $43,237 (direct costs: $29,214). July 1, 2002 – June 30, 2005.

 

Application for a Sub-Micron Particle Sizer. Internal Equipment Grant Program, TTUHSC School of Pharmacy, Amarillo, Texas. $12,865 ($12,500 matching funds). Funded. Co-Investigator. September, 2001.

 

Cancer Biology Research Center. TTUHSC School of Pharmacy Research Center. Amarillo, Texas. $122,000 total direct costs. Funded. Co-Investigator. October 1, 2001 – September 30, 2003.

 

Choline transporter mediated brain drug delivery. National Institutes of Health R-15 Academic Research Enhancement Award Program. Bethesda, Maryland. $140,320 total direct and indirect costs. Principal Investigator. Funded. Grant # 1 R15 NS41933-01. August 1, 2001 – July 31, 2003.

 

Choline transporter-mediated delivery of novel nicotinic agents to the brain for stroke prevention. American Heart Association, Texas Affiliate Beginning Grant in Aid program. Burlingame, California. $124,000 direct and indirect costs. Funded. Principal Investigator. Grant # 0160020Y July 1, 2001 – June 30, 2003.

 

Blood-brain barrier penetration of four Dupont compounds in brain and CSF. Dupont Pharmaceuticals, Wilmington, Delaware. $15,105 direct and indirect costs. Funded. Co-Investigator. July 26, 2001 – July 26, 2003.

 

Vascular Biology Research Center. TTUHSC School of Pharmacy Research Center. Amarillo, Texas. $115,287 total and direct costs. Funded. Co-Investigator. August 1, 2000 – July 31, 2002.

 

Atomic Absorption Spectrophotometer. Funding for packing, shipping and set-up of the spectrophotometer obtained from National Institute on Aging, NIH. TTUHSC Equipment Grant Program School of Pharmacy, Amarillo, Texas. $6,654. Funded. Principal Investigator. September, 2000.

 

Electrocardiographic System. Internal Equipment Grant Program, TTUHSC School of Pharmacy, Amarillo, Texas. $12,500. Funded. Co-Investigator. September 7, 2000.

 

An update of the evolving role of cholinesterase inhibitors in Alzheimer's disease and Dementia with Lewy bodies. Educational Grant. $5,385. Pfizer, Inc. Groton, Connecticut. Funded. Program for the Texas Society of Health-system Pharmacists Annual Meeting in San Antonio, Texas. April 11, 2000. Co-session coordinator.

 

Peptide delivery to the brain: In vitro and in vivo evaluation of endomorphin-I brain uptake. TTUHSC School of Pharmacy Internal Seed Grant Program, Amarillo, Texas. $5,920. Funded. Principal Investigator.

 

Diphenhydramine transport at the blood-brain barrier. AKPharma, Incorporated Pleasantville, New Jersey. $2,760 direct and indirect costs. Funded. Principal Investigator.

 

In situ brain perfusion measurement of drug permeability at the blood-brain barrier. Parke-Davis Pharmaceuticals, Ann Arbor, Michigan. $15,147 direct and indirect costs. Funded. Co-Investigator. January 1, 2000 – December 31, 2001.

 

Brain uptake of selected drugs by in situ perfusion: contribution of L-system transport. Parke-Davis Pharmaceuticals, Ann Arbor, Michigan. $5,850 direct and indirect costs. Funded. Co-Investigator October 18, 1999 – December 31, 2000.

 

Development and evaluation of pharmaceutical dosage forms: In vitro dissolution. Internal Equipment Grant Program, TTUHSC of Pharmacy, Amarillo, Texas. $11,805. Funded. Co-Investigator. August 20, 1999.

 

Drug Transport at the blood-brain barrier. Amgen, Incorporated. Thousand Oaks, California. $11,280 direct and indirect costs. Funded. Co-Investigator. July 1, 1999 – June 30, 2001.

 

Brain and cerebrospinal fluid (CSF) uptake of HIV protease inhibitors. Parke-Davis Pharmaceuticals, Ann Arbor, Michigan. $12,480 direct and indirect costs. Funded. Co-Investigator. July 1, 1999 – July 1, 2000.

 

Mechanism of Brain and CSF Uptake of Therapeutic Compounds. Dupont Pharmaceuticals, Wilmington, Delaware. $7,378 direct and indirect costs. Funded. Co-Investigator. April 26, 1999 – July 26, 2001.

 

Characterization of paclitaxel uptake into the central nervous system: Manipulation of the P-glycoprotein transporter to facilitate anticancer agent delivery to brain. TTUHSC School of Pharmacy Internal Seed Grant Program, Amarillo, Texas. $8,960. Funded. Principal Investigator. October 1, 1998 – August 26, 1999.

 

INSERM Travel Award. Awarded for an invitation to visit Institut National De La Santé Et De La Recherche Médicale (INSERM), Paris, France to assist in implementation of the updated in situ rat brain perfusion model used in my laboratory and continue collaborative efforts between my laboratory and the Unité de Neuro-pharmaco-nutrition, INSERM U.26. I visited INSERM in July, 1998. $500. Funded. Invited visiting scientist.

 

Assessment of native blood-brain barrier transport systems for site-directed brain drug delivery. American Association of Colleges of Pharmacy New Investigators Program. 1998-1999. $12,500. Principal Investigator. Funded.

 

Líneas celulares inmortales derivadas de sistema nervioso del ratón con trisomía 16, modelo animal de la trisomía 21 humana: Posibles modelos fisiopatológicos. English translation: Immortal cell lines derived from the nervous system of the trisomy 16 mouse, an animal model for human trisomy 21: Possible pathophysiological mechanisms. FONDECYT, Chile. $10,000. Foreign Principal Investigator. Funded. 1998-2001.

 

Use of the blood-brain barrier choline transporter as a vector for site-directed brain drug delivery: Evaluation of the choline carrier and it’s interactions with the Multidrug Resistance (or P-glycoprotein) and Multidrug Resistance Related proteins. Novartis AG Pharmaceuticals. Basel, Switzerland. $2,500. Funded. Principal Investigator. 1998-1999.

 

Novartis Pharma AG Travel Award. Awarded for an invitation to visit Novartis Basel to assist in implementation of the updated in situ rat brain perfusion model used in my laboratory. I visited Novartis Basel in June, 1998. $2,500. Funded. Invited visiting scientist.

 

Intramural Research Training Award Fellowship (IRTA), National Institute on Aging, National Institutes of Health, Bethesda, Maryland, 08/93-12/95. $76,167 salary support.

 

University of Kentucky Research Foundation Fellowship. Pre-doctoral research fellowship award. 08/92-07/93, funded $11,500.

 

Biomedical Research Support Fund Grant, University of Kentucky, College of Pharmacy, Elucidation of site(s) and mechanism(s) of aluminum permeation through the blood-brain barrier, 5/1/90-5/1/91. Funded. $1850 for supplies. Co-Principal Investigator.

 

Publications:

Van der Schyf C.J., Geldenhuys W.J. and Allen D.D. The Blood-Brain Barrier: Drug design considerations for drug delivery to the central nervous system. In preparation.

 

Gaasch J.A., Geldenhuys W.J., Bohn K.A., Allen D.D., Lockman P.R. and Van der Schyf C.J. The polycyclic cage amine NGP1-01 attenuates iron-induced cell death in brain endothelial cells. In preparation.

 

Gaasch J.A., Geldenhuys W.J., Bohn K.A., Egbert J.M., Allen D.D., Lockman P.R. and Van der Schyf C.J. Differential effect of nimodipine in attenuating iron-induced toxicity in RBE4 and N2α neuroblastoma cells and DI TNC1 astrocytes. In preparation.

 

Geldenhuys W.J., Manda V., Mittapalli R.K., Egbert J., Van der Schyf C.J., Crooks P.A., Dwoskin L.P., Allen D.D. and Lockman P.R. Predictive drug screening model for the potential transport of cationic substrates at the blood-brain barrier. In preparation.

 

Zhang Z., Lockman P.R., Geldenhuys W.J., Allen D.D., Dwoskin L.P. and Crooks P.A. Bis-Pyridinium compounds: novel nicotinic receptor ligands with high affinity for the blood-brain barrier choline transporter. Bioorganic & Medicinal Chemistry. In preparation.

 

Geldenhuys W.J., Gaasch K., Notareschi R. and Allen D.D. Open-source and Free Software Options in Teaching Doctor of Pharmacy Students: Addressing generational learning preferences for millennial learners. Submitted for publication.

 

Zhang Z., Lockman P.R., Mittapalli R.K., Allen D.D., Dwoskin L.P. and Crooks P.A. Bis-Pyridinium cyclophanes: novel ligands with high affinity for the blood-brain barrier choline transporter. Bioorganic & Medicinal Chemistry Letters. 18: 5622-5625. 2008.

 

Lockman P.R., Geldenhuys W.J., Manda V., Thomas F., Crooks P.A., Dwoskin L.P. and Allen D.D. Carrier mediated transport at the blood-brain barrier for the quaternary ammonium nicotinic receptor antagonist, N,N'-dodecyl-bis-picolinium bromide (bPiDDB). Journal of Pharmacology and Experimental Therapeutics. 324: 244-250. 2008.

 

Deuther-Conrad W., Patt J.T., Lockman P.R., Allen D.D., Patt M., Schildan A., Sabri O., Ganapathy V., Brust P. and Steinbach J. In Vivo Evaluation of the Nicotinic Acetylcholine Receptor Ligand [¹⁸F]Norchloro-fluoro-homoepibatidine (NCFHEB). European Neuropsychopharmacology. 18: 222-229. 2008.

 

Gaasch J.A., Geldenhuys W.J., Lockman P.R., Allen D.D. and Van der Schyf C.J. Voltage-gated calcium channels provide an alternate route for iron uptake in neuronal cell cultures. Neurochemical Research. 32: 1686-1693. 2007.

 

Gaasch J.A., Lockman P.R., Geldenhuys W.J., Allen D.D. and Van der Schyf C.J. Brain Iron Toxicity: Differential Responses of Astrocytes, Neurons and Endothelial Cells. Review. Neurochemical Research. 32: 1196-1208. 2007.

 

Geldenhuys W.J., Van der Schyf C.J., Hayes M. and Allen D.D. Receptor surface models in the classroom: Introducing molecular modeling to students in a 3D world. Journal of Chemical Education. 84: 979-982. June, 2007.

 

Schugar H., Green D.E., Bowen M.L., Scott L.E., Storr T., Böhmerle K., Thomas F., Allen D.D., Lockman P.R., Merkel M., Thompson K.H. and Orvig C. Combating Alzheimer's Disease by Designed Multifunctional Molecules for Metal Passivation. Angewandte Chemie Int. Ed. 46: 1716-1718. 2007. Angewandte Chemie. 119: 1746-1748. 2007.

 

Opazo P., Saud K., de Saint Pierre M., Cárdenas A.M., Allen D.D., Segura-Aguilar J., Caviedes R. and Caviedes P. Knockdown of amyloid precursor protein normalizes choline uptake and acetylcholine release in a cell line derived from the cerebral cortex of a trisomy 16 mouse, an animal model of Down syndrome. Journal of Neuroscience Research. 84: 1303-1310. 2006.

 

McCall K.L., Allen D.D. and Fike D. Correlation between advanced college coursework and academic success in pharmacy school. American Journal of Pharmaceutical Education. 70: 106. 2006.

 

Koziara J.M., Lockman P.R, Allen D.D. and Mumper R.J. The Blood-Brain Barrier and Brain Drug Delivery. Invited Review for the Journal of Nanoscience and Nanotechnology. Special Issue: "Nanotechnology in Advanced Drug Delivery." 2006. 6: 2712-2735. 2006.

 

Saud K., Arriagada C., Cárdenas A.M., Shimahara T., Allen D.D., Caviedes R. and Caviedes P. Neuronal dysfunction in Down syndrome: Contribution of neuronal models in cell culture. Journal of Physiology (Paris). 99:201-201. 2006.

 

Lockman P.R., Gaasch J.A., Van der Schyf C.J. and Allen D.D. Nicotine exposure does not alter plasma to brain choline transfer. Neurochemical Research. 31: 503-508. 2006.

 

Geldenhuys W.J., Gaasch K.E., Watson M., Allen D.D. and Van der Schyf C.J. Optimizing the use of open-source software applications: How to integrate available computer modeling options in drug discovery. Drug Discovery Today. 11: 127-132. 2006.

 

Paulson J.R., Roder K.E., McAfee G., Allen D.D., Van der Schyf C.J. and Abbruscato T.J. Tobacco smoke chemicals attenuate brain-to-blood potassium transport mediated by Na,K,2Cl-cotransporter during hypoxia-reoxygenation. Journal of Pharmacology and Experimental Therapeutics. 316: 248-254. 2006.

 

Allen D.D. and Geldenhuys W.J. Molecular modeling of blood-brain barrier nutrient transporters: In silico basis for evaluation of potential drug delivery to the central nervous system. Life Sciences.78: 1029-1033. 2006.

 

Geldenhuys W.J., Philip A.E., Lockman P.R., Miller B.L., McAfee J.H., McCurdy C.R. and Allen D.D. Inhibition of choline uptake by N-cyclohexylcholine, a high affinity ligand for the choline transporter at the Blood-Brain Barrier. Journal of Drug Targeting. 13: 259-266. 2005.

 

Lockman P.R., McAfee G., Geldenhuys W.J., Van der Schyf C.J., Abbruscato T.J. and Allen D.D. Brain uptake kinetics of nicotine and cotinine after chronic nicotine exposure. Journal of Pharmacology and Experimental Therapeutics. 314: 636-642. 2005.

 

Allen D.D., Caviedes R., Cárdenas A.M., Shimahara T., Segura-Aguilar J. and Caviedes P. Cell lines as in vitro models for drug screening and toxicity studies. Drug Development and Industrial Pharmacy. 31: 747-758. 2005.

 

Geldenhuys W.J., Lockman P.R., Nguyen T.H, Van der Schyf C.J., Crooks P.A., Dwoskin L.P. and Allen D.D. 3D-QSAR study of N-n-alkylnicotinium analogs at the blood-brain barrier choline transporter. Bioorganic & Medicinal Chemistry. 13: 4253-4261. 2005.

 

Lockman P.R., Van der Schyf C.J., Abbruscato T.J. and Allen D.D. Chronic nicotine exposure alters blood-brain barrier permeability and diminishes brain uptake of methyllycaconitine. Journal of Neurochemistry. 94: 37-44. 2005.

 

Cui Z., Lockman P.R., Atwood C.S., Hsu C.H., Gupte A., Allen D.D. and Mumper R.J. Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer’s and other CNS diseases. European Journal of Pharmaceutics and Biopharmaceutics. 59: 263-272. 2005.

 

Lockman P.R., Koziara J.M., Mumper R.J. and Allen D.D. Nanoparticle surface charges alter blood-brain barrier integrity and uptake. Journal of Drug Targeting. 12: 635-641. 2004.

 

Lockman P.R., McAfee J.H., Geldenhuys W.J. and Allen D.D. Cation transport specificity at the blood-brain barrier. Neurochemical Research. 29: 2233-2238. 2004.

 

Geldenhuys W.J., Lockman P.R., McAfee J.H., Fitzpatrick K.T., Van der Schyf C.J. and Allen D.D. Molecular modeling studies on the active binding site of the blood-brain barrier choline transporter. Bioorganic & Medicinal Chemistry Letters. 14: 3085-3092. 2004.

 

Koziara J.M., Lockman P.R., Allen D.D. and Mumper R.J. Paclitaxel nanoparticles for potential treatment of brain tumors. Journal of Controlled Release. 99: 259-269. 2004.

 

Crooks P.A., Ayers J.T., Xu R., Sumithran S.P., Grinevich V.P., Wilkins L.H., Deaciuc A.G., Allen D.D. and Dwoskin L.P. Development of subtype-selective ligands as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release. Bioorganic & Medicinal Chemistry Letters. 14: 1869-1874. 2004.

 

Smith Q.R. and Allen D.D. In situ brain perfusion technique. Methods in Molecular Medicine. 89: 209-218. 2003.

 

Lockman P.R., Oyewumi M., Koziara J., Roder K.E., Mumper R.J. and Allen D.D. Brain uptake of thiamine-coated nanoparticles. Journal of Controlled Release. 93: 271-282. 2003.

 

Koziara J.M., Lockman P.R., Allen D.D. and Mumper R.J. In situ blood-brain barrier transport of nanoparticles. Pharmaceutical Research. 20: 1772-1778. 2003.

 

Allen D.D. and Lockman P.R. Invited review. The blood-brain barrier choline transporter as a brain drug delivery vector. Life Sciences. 73: 1609-1615. 2003.

 

Lockman P.R., Mumper R.J. and Allen D.D. Evaluation of blood-brain barrier thiamine efflux using the in situ rat brain perfusion method. Journal of Neurochemistry. 86: 637-34. 2003.

 

Lockman P.R., Koziara J., Paulson J.R., Roder K.E., Abbruscato T.J., Mumper R.J. and Allen D.D. In vivo and in vitro assessment of baseline blood-brain barrier parameters in the presence of novel nanoparticles. Pharmaceutical Research. 20: 705-713. 2003.

 

Crossgrove J.S., Allen D.D., Bukaveckas B.L., Rhineheimer S.S. and Yokel R.A. Manganese distribution across the blood-brain barrier. I. Evidence for carrier-mediated influx of manganese citrate as well as manganese and manganese transferring. Neurotoxicology. 24: 3-13. 2003.

 

Allen D.D., Lockman P.R., Roder K.E., Dwoskin L.P and Crooks P.A. Active transport of high affinity choline and nicotine analogs into the central nervous system by the blood-brain barrier choline transporter. Journal of Pharmacology and Experimental Therapeutics. 304:1268-1274. 2003.

 

Allen D.D., Nadesan B., Lee J.W., Bickel U., Haase M.R. and Arif A. Evaluation of novel teaching approaches in the Texas Tech University HSC School of Pharmacy elective, Drugs of Abuse. Journal of Pharmacy Teaching. 10: 1-16. 2002.

 

Crowe A.P., Lockman P.R., Abbruscato T.J. and Allen D.D. Novel choline transport characteristics in Caco-2 cells. Drug Development and Industrial Pharmacy. 28(7): 773-781. 2002.

 

Lockman P.R. and Allen D.D. Invited Review. The transport of choline: A review. Drug Development and Industrial Pharmacy. 28(7): 749-771. 2002.

 

Cárdenas A.M., Arriagada C., Allen D.D., Cortes J.F., Martín J., Couve E., Rapoport S.I., Shimahara T., Caviedes R. and Caviedes P. Neuronal Cell lines form the hippocampus of the normal and trisomy 16 mouse fetus (A model for Down Syndrome) exhibit neuronal markers, cholinergic function and functional neurotransmitter receptors. Experimental Neurology. 177: 159-170. 2002.

 

Allen D.D., Cárdenas A.M., Arriagada C., Bennett L.B., Garcia J., Caviedes R., Rapoport S.I. and Caviedes P. A dorsal root ganglia cell line derived from trisomy 16 fetal mice, a model for Down syndrome. Neuroreport. 13: 491-6. 2002.

 

Cárdenas A.M., Allen D.D., Arriagada C., Olivares A., Bennett L.B., Caviedes R., Dagnino-Subiabre A., Mendoza I.E., Segura-Aguilar J., Rapoport S.I. and Caviedes P. Establishment and characterization of immortalized neuronal cell lines derived from the spinal cord of normal and trisomy 16 fetal mice, an animal model of Down Syndrome. Journal of Neuroscience Research.68: 46-58. 2002.

 

Lockman P.R., Mumper R.J., Khan M.A. and Allen D.D. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Development and Industrial Pharmacy. 28(1): 1-13. 2002.

 

Allen D.D. and Bond C.A. Prepharmacy predictors of success in Pharmacy School: Grade point averages, pharmacy college admissions test, communication abilities and critical thinking skills. Pharmacotherapy.21: 842-849. 2001.

 

Lockman P.R., Shum S. and Allen D.D. Case Report: Visual toxicity in acute isoniazid overdose. Internet Journal of Medical Toxicology. 4(3): 21. July, 2001. Website address for the Case Report: http://www.ijmt.net/4_3/4_3_21.htm.

 

Rojas-Fernandez C.H., Lanctôt K.L., Allen D.D. and McKnight C. Pharmacotherapy of behavioral and psychological symptoms of dementia: Time for a different paradigm? Pharmacotherapy. 21: 74-102. 2001.

 

Lockman P.R., Roder K.E. and Allen D.D. Inhibition of the rat blood brain-barrier choline transporter by manganese chloride. Journal of Neurochemistry. 79:588-94. 2001.

 

Allen D.D. and Smith Q.R. Characterization of the blood-brain barrier choline transporter using the in situ brain perfusion technique. Journal of Neurochemistry. 76: 1032-1041. 2001.

 

Allen D.D., Martín J., Arriagada C., Cárdenas A.M., Rapoport S.I., Caviedes R. and Caviedes P. Impaired cholinergic function in cell lines derived from the cerebral cortex of normal and trisomy 16 mice. European Journal of Neuroscience. 12: 3259-3264. 2000.

 

Professional Publications:
Allen D.D. It is “Status Grow” at the Northeastern Ohio Universities College of Pharmacy. Bulletin of The Ohio Society of Health-System Pharmacists. 25: 5. 2008.

 

Allen D.D. Northeastern Ohio Universities College of Pharmacy poised to welcome inaugural class. Bulletin of The Ohio Society of Health-System Pharmacists. 27: 8. 2007.

 

Allen D.D. and Calhoun L.D. Administrative retreats: A new twist on an old approach to avoid “administrative isolation.” “Viewpoint” in the American Journal of Pharmaceutical Education. 70: 147. 2006.

 

Allen D.D. Northeastern Ohio Universities College of Pharmacy: A model for interdisciplinary training of health care professionals. Bulletin of The Ohio Society of Health-System Pharmacists. 26: 6-7. 2006.

 

Allen D.D., Penn M.A. and Nora L.M. Interdisciplinary healthcare education: Fact or fiction? “Viewpoint” in the American Journal of Pharmaceutical Education. 70: 39. 2006.

 

Allen D.D. TSHP’s 56^th Annual Seminar and Industry Colleagues in Health Care Forum: An event for networking, learning and just plain good ole Texas fun! Journal of the Texas Society of Health-System Pharmacists. Volume 5(1): 3. Spring 2004.

 

Allen D.D. What do you want to be when you grow up? Pharmacy organizations can help. Counting by fours. March 2004. Student Section Newsletter of the Texas Society of Health-System Pharmacists.

 

Allen D.D. Who Moved TSHP’s Cheese? TSHP's new management structure is in place. Journal of the Texas Society of Health-System Pharmacists. Volume 4(3): 3. Fall 2003.

 

Allen D.D. Heroes, mentors and the gift. TSHP Incoming Presidential Installation Address. Journal of the Texas Society of Health-System Pharmacists. Volume 4(2): 27-28. Summer 2003.

 

Allen D.D. Therapies for neurodegenerative diseases under way. Article about potential new therapies in central nervous system disorders published in the section “Texas Tech Health.” Amarillo Daily News, Volume 3(27): 2C. January 27, 2003.

 

Allen D.D. National Pharmacy Week, October 20-26, 2002: Let’s take time to promote pharmacy! Texas Society of Health-System Pharmacists Newsletter. Volume 31(5): Fall 2002. (Withdrawn due to delayed publication).

 

Allen D.D. and Shields B.T. Pharmacy is impacted by multiple pieces of legislation during the 77^th Texas Legislative Session. Journal of the Texas Society of Health-System Pharmacists. Volume 2(3): 103-105. October/December 2001.

 

Allen D.D. Texas Society of Health-System Pharmacists members will lead the Texas State Board of Pharmacy as presidential officers for fiscal year 2002. Texas Society of Health-System Pharmacists Newsletter. Volume 30: 5. September/October 2001.

 

Allen D.D. Déjà vu all over again? Texas Society of Health-System Pharmacists member receives American Association of Health-Systems Pharmacists Research and Education Foundation research award for the second consecutive year. Texas Society of Health-System Pharmacists Newsletter. Volume 30: 7. September/October 2001.

 

Allen D.D. TSHP State Pharmacy Board Bits. An email newsletter from the Texas Society of Health-System Pharmacists providing updates from the regular meetings of the Texas State Board of Pharmacy. Editor and Co-author. Volume 1. August, 2001; Volume 2. November, 2001.

 

Allen D.D. Effective teamwork for legislative and regulatory processes: Some of the TSHP team players may surprise you! Texas Society of Health-System Pharmacists Newsletter. Special Legislative Issue: pp. 6-7. June, 2001.

 

Easterday L. and Allen D.D. Technician certification and registration: Where do things stand now? Texas Society of Health-System Pharmacists Newsletter. Special Legislative Issue: p.7. June, 2001.

 

Allen D.D. 2001 Pharmacy Day at the Capitol is a HUGE success!!! Texas Society of Health-System Pharmacists Newsletter. Volume 30(3): 4-5. May/June, 2001.

 

Allen D.D. Texas Society of Health-Systems Pharmacists (TSHP) member receives two American Association of Health-Systems Pharmacists (ASHP) Research and Education (R&E) Foundation 2000 research awards. Texas Society of Health-System Pharmacists Newsletter. Volume 30(1): 3. January/February, 2001.

 

Allen D.D. Pharmacy Day at the Capitol 2001. Texas Society of Health-System Pharmacists Newsletter. Volume 30(1): 5. January/February, 2001.

 

Allen D.D. RX Legislative Bytes. Volumes 1-9 and 4 Supplemental Volumes; An email newsletter from the Texas Society of Health-System Pharmacists providing updates every two weeks from the 2001 Texas Legislative Session. Editor and Co-author.

 

Schmitt H. and Allen D.D. Linezolid for the treatment of vancomycin resistant and multidrug resistant organisms. Journal of the Texas Society of Health-System Pharmacists. Volume 1(3): 4-5. July/September, 2000.

 

Allen D.D. Preparing for the next Texas Legislature Pharmacy Lobby Day. Journal of the Texas Society of Health-System Pharmacists. Volume 1(2): 37. July/August 2000.

 

Dugie B.K. and Allen D.D. Amprenavir: New treatment for the treatment of Human Immunodeficiency Virus. Journal of the Texas Society of Health-System Pharmacists. Volume 1(2): 9-10. April/June, 2000.

 

Allen D.D. Preparing for the next Texas Legislature Pharmacy Lobby Day. Texas Society of Health-System Pharmacists Newsletter. Volume 29(4): 11. July/August 2000.

 

Allen D.D. Dr. Roger W. Anderson is new Texas State Board of Pharmacy appointee. Texas Society of Health-System Pharmacists Newsletter. Volume 28(7): 12. November/December 1999.

 

Busti A., Fisher, C.W. and Allen D.D. Finasteride and the potentially pregnant woman. Texas Society of Health-System Pharmacists Newsletter. Volume 28(4): 6-9. May/June. 1999.

 

Allen D.D. The role of Texas Society of Health-System Pharmacist's lobbyist, Brad Shields. Texas Society of Health-System Pharmacists Newsletter. Volume 30(3) Special Legislative Supplemental Issue: 2. 1999.

 

Rodriguez S.L., Newsom J.F., Allen D.D. and Fisher, C.W. The availability of Viagra® over the internet. Texas Society of Health-System Pharmacists Newsletter. Volume 28(2): 4,6. March/April, 1999.

 

Barnidge J., Fisher C.W., Bouma C. and Allen D.D. Moclobemide (Aurorix®, Manerix®, Molcamine®). Texas Society of Health-System Pharmacists Newsletter. Volume 27(5): 8, 10. November, December, 1998.

 

Metting T.L., Fisher C.W. and Allen D.D. Roche laboratories recall Posicor® (mibefradil). Texas Society of Health-System Pharmacists Newsletter. Volume 27(4): 8-9. September/October, 1998.

 

Stallworth K.L. and Allen D.D. Rizatriptan: A new treatment for acute migraine headaches. Texas Society of Health-System Pharmacists Newsletter. Volume 27(3): 10-11. July/August, 1998.

 

Allen D.D. Chronic heartburn sufferers may be only a diagnosis away from relief. Article about gastroesophageal reflux disease published in the section “Texas Tech Health.” Amarillo Daily News, Volume 89(180): 9A. June 1, 1998.

 

Turner S. and Allen D.D. Wellbutrin SRâ vs. Zybanâ (Bupropion). Texas Society of Health-System Pharmacists Newsletter. Volume 27(2): 8-9. May, 1998.

 

Allen D.D. TTUHSC School of Pharmacy: A dynamic curriculum to meet the changing roles of pharmacists. in PharmDiscourse. School of Pharmacy Newsletter. September 1996, Volume 2.

 

Books and/or Chapters:

Allen D.D. and Barone L.D. Chapter Editors. Chapter Authors: Allen D.D., Barone L.D., Brennan C., Canada T., Clegg C., Frei B.L., Lake-Wallace S.E., Patry R.A., Piñón M., Purcell R.K., Ridings-Myhra J. and Wilson C. Partnerships with Schools. In: Preceptor’s Handbook for Pharmacists, 2^nd Edition. Co-Authors and Co-Editors: Cuellar L.M. and Ginsburg D.B. American Society of Health-System Pharmacists. Bethesda, Maryland. In press.

 

Egbert J., Geldenhuys W.J., Thomas F., Lockman P.R., Mumper R.J. and Allen D.D. (2006) Nanoparticle targeting for drug delivery across the blood brain. In: Oral and Parenteral Lipid-Based Drug Delivery: Concepts and Case Studies. Ed. Wasan K. John Wiley & Sons, Inc. Hoboken, New Jersey.

 

Smith Q.R., Fisher C. and Allen D.D. (2001) The role of plasma protein binding in drug delivery to brain. In: Blood-brain barrier: Drug delivery and brain pathology. Eds. Kobiler D., Lustig S., Shapira S. Kluwer Academic/Plenum, New York.

 

Yokel R.A., Allen D.D. and McNamara P.J. (1993) Microdialysis as a method to study the transport of neurotoxic metals through the blood-brain barrier: studies with aluminium. In: CNS Barriers and Modern CSF Diagnostics. Eds. Felgenhauer K., Holzgraefe M., Prange H.W. VCH, Weinheim, Germany.